Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has announced its participation in the HC Wainwright "HCW@Home" virtual series. The company's CEO Neal Walker and senior leadership team will engage in a fireside chat scheduled for May 16, 2025, at 1:00 PM EDT. Investors and interested parties can access the live webcast and a 30-day replay through the Events page on the company's website at aclaristx.com.
Aclaris Therapeutics (NASDAQ: ACRS), un'azienda biofarmaceutica in fase clinica specializzata in trattamenti per malattie immuno-infiammatorie, ha annunciato la sua partecipazione alla serie virtuale "HCW@Home" organizzata da HC Wainwright. Il CEO Neal Walker e il team di leadership senior dell'azienda parteciperanno a una conversazione informale prevista per il 16 maggio 2025 alle 13:00 EDT. Investitori e interessati potranno seguire la diretta streaming e la replica disponibile per 30 giorni tramite la pagina Eventi del sito web aziendale aclaristx.com.
Aclaris Therapeutics (NASDAQ: ACRS), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para enfermedades inmuno-inflamatorias, ha anunciado su participación en la serie virtual "HCW@Home" de HC Wainwright. El CEO Neal Walker y el equipo de liderazgo senior de la compañía participarán en una charla informal programada para el 16 de mayo de 2025 a la 1:00 PM EDT. Inversionistas y personas interesadas pueden acceder a la transmisión en vivo y a una repetición disponible por 30 días a través de la página de Eventos en el sitio web de la compañía aclaristx.com.
Aclaris Therapeutics (NASDAQ: ACRS)는 면역 염증 질환 치료를 전문으로 하는 임상 단계 바이오제약 회사로, HC Wainwright의 가상 시리즈 "HCW@Home"에 참여한다고 발표했습니다. 회사의 CEO Neal Walker와 고위 경영진이 2025년 5월 16일 오후 1시 EDT에 예정된 화롯가 대화에 참여할 예정입니다. 투자자 및 관심 있는 분들은 회사 웹사이트 aclaristx.com의 이벤트 페이지를 통해 생중계 및 30일간 다시보기를 이용할 수 있습니다.
Aclaris Therapeutics (NASDAQ : ACRS), une société biopharmaceutique en phase clinique spécialisée dans les traitements des maladies immuno-inflammatoires, a annoncé sa participation à la série virtuelle "HCW@Home" organisée par HC Wainwright. Le PDG Neal Walker et l'équipe de direction senior de l'entreprise participeront à une discussion informelle prévue le 16 mai 2025 à 13h00 EDT. Les investisseurs et les personnes intéressées peuvent accéder à la diffusion en direct ainsi qu'à un replay disponible pendant 30 jours via la page Événements du site web de la société aclaristx.com.
Aclaris Therapeutics (NASDAQ: ACRS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Behandlung immun-entzündlicher Erkrankungen spezialisiert hat, hat seine Teilnahme an der virtuellen Reihe "HCW@Home" von HC Wainwright bekannt gegeben. Der CEO Neal Walker und das Führungsteam des Unternehmens werden an einem Kaminabend-Gespräch teilnehmen, das für den 16. Mai 2025 um 13:00 Uhr EDT geplant ist. Investoren und Interessierte können den Live-Webcast sowie eine 30-tägige Wiederholung über die Veranstaltungsseite auf der Unternehmenswebsite aclaristx.com abrufen.
- None.
- None.
WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris’ Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright “HCW@Home” series.
The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and archived webcast of the event will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
When is Aclaris Therapeutics (ACRS) presenting at the HC Wainwright conference?
Who will represent Aclaris Therapeutics (ACRS) at the HC Wainwright conference?
How can investors access Aclaris Therapeutics' (ACRS) HC Wainwright presentation?
What is Aclaris Therapeutics' (ACRS) main business focus?
